Drug Profile
Avibactam/aztreonam - AbbVie/AstraZeneca/Pfizer
Alternative Names: ATM-AVI; Aztreonam-avibactam; PF-06947387Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AbbVie; AstraZeneca; Biomedical Advanced Research and Development Authority; Innovative Medicines Initiative; Pfizer
- Class Amides; Anti-infectives; Antibacterials; Heterocyclic bicyclo compounds; Monobactams; Small molecules; Sulfates
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gram-negative infections
- Phase II Intra-abdominal infections
Most Recent Events
- 11 Oct 2023 Antimicrobial and adverse events data from a phase III REVISIT trial in Gram negative infection presented at the IDWeek 2023 (IDW-2023)
- 11 Oct 2023 Antimicrobial data from a preclinical trial in Gram-negative infections presented at the IDWeek 2023 (IDW-2023)
- 11 Oct 2023 Antimicrobial data from a preclinical trial in Gram-negative infections presented at the IDWeek 2023 (IDW-2023)